Comparison of post remission chemotherapy in older acute myeloid leukemia patients: a study from DATAML and SAL registries. Prof. Christian Récher, Service d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de...
More
Comparison of post remission chemotherapy in older acute myeloid leukemia patients: a study from DATAML and SAL registries. Prof. Christian Récher, Service d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France Prof. Pierre-Yves Dumas, Service d’Hématologie Clinique et de Thérapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, France Christoph Röllig, Medizinische Klinik und Poliklinik I, Universitätsklinikum TU Dresden, Dresden, Germany Emilie Bérard, MD, PhD, Unité de Soutien Méthodologique à la Recherche, Centre Hospitalier Universitaire de Toulouse, Toulouse, France Background In older fit AML patients having achieved first complete remission, there was no established value of intensive consolidation therapy according to the ELN 2017 guidelines whereas ELN 2022 propose that those patients should receive consolidation therapy with intermediate dose cytarabine (IDAC, 500-1000 mg/m²/12h, d1-3, for
Less
